
HKSEBasic MaterialsIndustrial Materials
Latest quote
HK$16.00
−HK$1.34 · -7.73%
CMOC Group Limited, through its diverse subsidiaries, is a multifaceted enterprise engaged in the entire value chain from the extraction, processing, and refining to the commercialization of numerous metallic resources. These include essential minerals like copper, cobalt, molybdenum, tungsten, niobium, and phosphates, alongside other base and rare metals. The company's extensive product offerings encompass molybdenum oxide, ferromolybdenum, concentrates of molybdenum, tungsten, and copper, cobalt hydroxide, ferroniobium, phosphate fertilizer, and precious metals such as gold and silver. Beyond its core mining activities, CMOC also undertakes the processing and distribution of mineral products, trades in molybdenum and tungsten commodities, and participates in the international import and export of both goods and technology. Its operational scope further extends into service sectors, covering hotel management, consulting, corporate operations, asset management, logistics, and transportation services. CMOC maintains a substantial global footprint, with active operations across China, Australia, Brazil, the Democratic Republic of the Congo, Switzerland, and various other international locations. The company was initially established in 2006 under the name China Molybdenum Co., Ltd., and its corporate headquarters are situated in Luoyang, People's Republic of China.
Latest quote
HK$16.00
−HK$1.34 · -7.73%
Regular session · HKT · Market data may be delayed.
CMOC Group Limited, through its diverse subsidiaries, is a multifaceted enterprise engaged in the entire value chain from the extraction, processing, and refining to the commercialization of numerous metallic resources. These include essential minerals like copper, cobalt, molybdenum, tungsten, niobium, and phosphates, alongside other base and rare metals. The company's extensive product offerings encompass molybdenum oxide, ferromolybdenum, concentrates of molybdenum, tungsten, and copper, cobalt hydroxide, ferroniobium, phosphate fertilizer, and precious metals such as gold and silver. Beyond its core mining activities, CMOC also undertakes the processing and distribution of mineral products, trades in molybdenum and tungsten commodities, and participates in the international import and export of both goods and technology. Its operational scope further extends into service sectors, covering hotel management, consulting, corporate operations, asset management, logistics, and transportation services. CMOC maintains a substantial global footprint, with active operations across China, Australia, Brazil, the Democratic Republic of the Congo, Switzerland, and various other international locations. The company was initially established in 2006 under the name China Molybdenum Co., Ltd., and its corporate headquarters are situated in Luoyang, People's Republic of China.
Day range
Current HK$16.00
52-week range
Current HK$16.00
Regular session · HKT · Market data may be delayed.
CMOC Group Limited, through its diverse subsidiaries, is a multifaceted enterprise engaged in the entire value chain from the extraction, processing, and refining to the commercialization of numerous metallic resources. These include essential minerals like copper, cobalt, molybdenum, tungsten, niobium, and phosphates, alongside other base and rare metals. The company's extensive product offerings encompass molybdenum oxide, ferromolybdenum, concentrates of molybdenum, tungsten, and copper, cobalt hydroxide, ferroniobium, phosphate fertilizer, and precious metals such as gold and silver. Beyond its core mining activities, CMOC also undertakes the processing and distribution of mineral products, trades in molybdenum and tungsten commodities, and participates in the international import and export of both goods and technology. Its operational scope further extends into service sectors, covering hotel management, consulting, corporate operations, asset management, logistics, and transportation services. CMOC maintains a substantial global footprint, with active operations across China, Australia, Brazil, the Democratic Republic of the Congo, Switzerland, and various other international locations. The company was initially established in 2006 under the name China Molybdenum Co., Ltd., and its corporate headquarters are situated in Luoyang, People's Republic of China.
Day range
Current HK$16.00
52-week range
Current HK$16.00
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 206.44B CNY | 213.03B CNY | 186.27B CNY | 172.99B CNY | 173.86B CNY |
| Cost of goods sold | 157.4B CNY | 177.77B CNY | 168.44B CNY | 156.93B CNY | 157.54B CNY |
| Gross profit | 49.44B CNY | 35.25B CNY | 17.83B CNY | 16.06B CNY | 16.32B CNY |
| Research and development | 420.51M CNY | 353.97M CNY | 327.09M CNY | 388.61M CNY | 272.39M CNY |
| Selling, general, and administrative | 854.18M CNY | 2.23B CNY | 858.22M CNY | 760.48M CNY | 606.97M CNY |
| Operating expenses | 14.11B CNY | 9.99B CNY | 4.54B CNY | 6.17B CNY | 7.51B CNY |
| Interest income | 1.64B CNY | 2.61B CNY | 1.36B CNY | 1.19B CNY | 1.04B CNY |
| Interest expense | 2.99B CNY | 4.04B CNY | 4.14B CNY | 2.81B CNY | 2.22B CNY |
| Depreciation and amortization | 7.11B CNY | 2.7B CNY | 2.81B CNY | 4.49B CNY | 3.99B CNY |
| Operating income | 35.33B CNY | 25.27B CNY | 13.29B CNY | 9.89B CNY | 8.79B CNY |
| Net income | 20.34B CNY | 13.53B CNY | 8.25B CNY | 6.07B CNY | 5.11B CNY |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.2779
2025 complete year+598.2% since 2021
2026 partial: HK$0.4362
HK$0.0398
2,021
HK$0.0838
2,022
HK$0.0938
2,023
HK$0.1696
2,024
HK$0.2779
2,025
HK$0.4362
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Sep 1, 2026 | HK$0.1098Quarterly | Sep 2, 2026 | Sep 24, 2026 |
Dividend | May 18, 2026 | HK$0.3264Annual | May 19, 2026 | Jun 24, 2026 |
Dividend | Jun 19, 2025 | HK$0.2779Annual | Jun 20, 2025 | Jul 18, 2025 |
Dividend | Jun 27, 2024 | HK$0.1696Annual | Jun 28, 2024 | Jul 26, 2024 |
Dividend | Jun 29, 2023 | HK$0.0938Annual | Jun 30, 2023 | Jul 27, 2023 |
Dividend | Jun 29, 2022 | HK$0.0838Annual | Jun 30, 2022 | Jul 27, 2022 |
Ex-dividend Sep 1, 2026
HK$0.1098
Quarterly
Record Sep 2, 2026 · Payment Sep 24, 2026
Ex-dividend May 18, 2026
HK$0.3264
Annual
Record May 19, 2026 · Payment Jun 24, 2026
Ex-dividend Jun 19, 2025
HK$0.2779
Annual
Record Jun 20, 2025 · Payment Jul 18, 2025
Ex-dividend Jun 27, 2024
HK$0.1696
Annual
Record Jun 28, 2024 · Payment Jul 26, 2024
Ex-dividend Jun 29, 2023
HK$0.0938
Annual
Record Jun 30, 2023 · Payment Jul 27, 2023
Ex-dividend Jun 29, 2022
HK$0.0838
Annual
Record Jun 30, 2022 · Payment Jul 27, 2022
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS114.88M0.02%646.2B USD0.05%$87.14+1.00%
Vanguard FTSE Emerging Markets ETFVWO110.61M0.07%162.3B USD0.06%$60.35+0.69%
iShares Core MSCI Emerging Markets ETFIEMG95.93M0.06%162.15B USD0.09%$82.57+1.21%
iShares Core MSCI China ETF2801.HK39.44M0.32%12.21B HKD0.20%HK$24.20+1.51%
iShares China Large-Cap ETFFXI28.69M0.69%4.12B USD0.73%$34.49+0.41%
iShares Core MSCI Asia ex Japan ETF3010.HK25.9M0.07%37.02B HKD0.28%HK$90.32-1.12%
iShares Core MSCI Asia ex Japan ETF83010.HK22.14M0.07%31.64B CNY0.28%CN¥77.04-1.76%
Avantis Emerging Markets Equity ETFAVEM21.18M0.07%28.6B USD0.33%$95.35+1.29%
Vanguard Total International Stock ETFVXUS
Vanguard FTSE Emerging Markets ETFVWO
iShares Core MSCI Emerging Markets ETFIEMG
iShares Core MSCI China ETF2801.HK
iShares China Large-Cap ETFFXI
iShares Core MSCI Asia ex Japan ETF3010.HK
iShares Core MSCI Asia ex Japan ETF83010.HK
Avantis Emerging Markets Equity ETFAVEMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.